Michael Vaclaw, MD
Family Medicine · Bartlesville, OKNPI 1942295308
Payments from drug & device makers
Across 204 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$761
- Astellas Pharma US Inc$322
- AbbVie$313
- Lilly USA, LLC$296
- AstraZeneca$289
- Amgen$247
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,29698%
- Education$652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 45 | $761 |
| Astellas Pharma US Inc | 16 | $322 |
| AbbVie(2 entities) | 18 | $313 |
| Lilly USA, LLC | 21 | $296 |
| AstraZeneca | 19 | $289 |
| Amgen | 14 | $247 |
| Pfizer | 15 | $230 |
| Boehringer Ingelheim | 9 | $149 |
| Merck | 5 | $61 |
| Johnson & Johnson | 5 | $59 |
| Abbott | 3 | $51 |
| Ultragenyx Pharmaceutical Inc. | 2 | $48 |
| GSK | 3 | $44 |
| Organon | 3 | $42 |
| Exact Sciences | 2 | $38 |
| Eisai Inc. | 2 | $36 |
| Dexcom, Inc. | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $34 |
| Corium, LLC | 1 | $30 |
| Novartis | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Abiomed | 1 | $22 |
| Antares Pharma, Inc. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Biogen | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Vertex | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
How this compares
$3,361 in reported general payments places this provider in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 266 | $111,706 |
| OzempicSemaglutide | 77 | $81,191 |
| MounjaroTirzepatide | 53 | $59,626 |
| TrulicityDulaglutide | 55 | $56,693 |
| XareltoRivaroxaban | 111 | $46,297 |
| JardianceEmpagliflozin | 41 | $31,244 |
| FarxigaDapagliflozin Propanediol | 37 | $23,258 |
| JanuviaSitagliptin Phosphate | 48 | $19,605 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $14,060 |
| Atorvastatin Calcium | 636 | $10,933 |
| GemtesaVibegron | 40 | $10,351 |
| MyrbetriqMirabegron | 33 | $9,081 |
| BrilintaTicagrelor | 21 | $8,969 |
| Pantoprazole Sodium | 426 | $8,478 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,831 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $296 | $116,319108 claims |
| PfizerEliquis | $230 | $111,706266 claims |
| Novo NordiskOzempic | $761 | $81,19177 claims |
| Johnson & JohnsonXarelto | $59 | $46,297111 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $289 | $38,18270 claims |
| Boehringer IngelheimJardiance | $149 | $31,24441 claims |
| MerckJanuvia | $61 | $19,60548 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta | $44 | $15,15234 claims |
| Astellas Pharma US IncMyrbetriq | $322 | $9,08133 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $15 | $5,44018 claims |
| AbbVieLumigan | $313 | $3,23612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Bartlesville
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.